PMID- 19545680
OWN - NLM
STAT- MEDLINE
DCOM- 20090928
LR  - 20131121
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 41
IP  - 5
DP  - 2009 Jun
TI  - Clinical application of Cordyceps sinensis on immunosuppressive therapy in renal 
      transplantation.
PG  - 1565-9
LID - 10.1016/j.transproceed.2009.02.085 [doi]
AB  - OBJECTIVE: We sought to explore the adjunctive effects of Cordyceps sinensis (CS) 
      in clinical renal transplantation. MATERIALS AND METHODS: Patients (n = 202) were 
      divided randomly by lottery into a treatment (n = 93) and a control group (n = 
      109). Patients in the treatment group were treated with CS 1.0 g 3 times a day in 
      addition to the immunosuppressive regimen given to the control group. We compared 
      patient and graft survivals, incidence, time and severity of acute rejection 
      episodes, chronic allograft nephropathy (CAN), hepatotoxicity and nephrotoxicity, 
      biochemistry parameters including indicators of liver and kidney functions, fats, 
      proteinuria, dosages, and whole blood concentrations of cyclosporine (CsA). 
      RESULTS: Patient and graft survival rates, serum creatinine (SCr), and blood urea 
      nitrogen (BUN) were not significantly different between the 2 groups (P > .05). 
      Serum uric acid (UA) and 24-hour urinary total protein (24-hour UTP) were 
      significantly lower in the treatment group than in the control group (P < .05). 
      The incidences (11.83% vs 15.60%) and times to acute renal allograft rejection 
      (23.48 +/- 7.22 vs 22.27 +/- 8.03 days posttransplantation) were not 
      significantly different between the treated and control groups (P > .05). 
      Patients receiving thymoglobulin antirejection therapy (3 cases) were fewer in 
      the heated versus control group (13 cases; P = .014). The incidences of 
      hepatotoxicity and nephrotoxicity in the treated group were 12.90% and 19.35%, 
      significantly lower than 24.77% and 33.94% in the control group, respectively (P 
      < .05). At 2 to 6 months posttransplantation, the CsA dosages in the treated 
      group were significantly lower than those in the control group (P < .05). The 
      whole blood trough CsA concentrations in the treated group were significantly 
      lower than those in the control group at 3 to 6 months posttransplantation (P < 
      .05). The decreasing trends of the 2 aforementioned parameters in the treatment 
      group were approximately linear among treated subjects compared with 
      approximately quadratic in the control group (P < .05). The incidence of CAN in 
      the treated group was 7.53%, which was significantly lower than 18.35% in the 
      control group (P = .024). The 24-hour UTP level in CAN patients within the 
      treated group was significantly lower than the control group after 
      transplantation (P = .045). The differences in total bilirubin, SCr, serum UA, 
      and total cholesterol levels among otherwise normal patients in the treated group 
      were significantly lower than those among the control group (P < .05). 
      CONCLUSIONS: The use of CS may allow decreased dosages and concentrations of CsA 
      causing fewer side effects without an increased risk of acute rejection. In 
      addition, CS with reduced dose CsA may decrease proteinuria and retard CAN 
      progression.
FAU - Li, Y
AU  - Li Y
AD  - Department of Renal Transplantation, Center of Nephropathy, The First Affiliated 
      Hospital, Medical College, Xi'an Jiaotong University, Xi'an, Shannxi, People's 
      Republic of China.
FAU - Xue, W-J
AU  - Xue WJ
FAU - Tian, P-X
AU  - Tian PX
FAU - Ding, X-M
AU  - Ding XM
FAU - Yan, H
AU  - Yan H
FAU - Pan, X-M
AU  - Pan XM
FAU - Feng, X-S
AU  - Feng XS
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Immunosuppressive Agents)
RN  - 268B43MJ25 (Uric Acid)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Blood Urea Nitrogen
MH  - Cordyceps/*immunology
MH  - Creatinine/blood
MH  - Female
MH  - Graft Survival/immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Kidney Diseases/classification/surgery
MH  - Kidney Transplantation/*immunology
MH  - Male
MH  - Middle Aged
MH  - Proteinuria/prevention & control
MH  - Uric Acid/blood
MH  - Young Adult
EDAT- 2009/06/24 09:00
MHDA- 2009/09/29 06:00
CRDT- 2009/06/24 09:00
PHST- 2008/08/28 00:00 [received]
PHST- 2008/12/22 00:00 [revised]
PHST- 2009/02/09 00:00 [accepted]
PHST- 2009/06/24 09:00 [entrez]
PHST- 2009/06/24 09:00 [pubmed]
PHST- 2009/09/29 06:00 [medline]
AID - S0041-1345(09)00286-3 [pii]
AID - 10.1016/j.transproceed.2009.02.085 [doi]
PST - ppublish
SO  - Transplant Proc. 2009 Jun;41(5):1565-9. doi: 10.1016/j.transproceed.2009.02.085.